Cell CycleBlocking Drugs Ibrance Kisqali Verzenio & Breast Cancer

Cell Cycle-Blocking Drugs Ibrance, Kisqali, Verzenio & Breast Cancer

05:09 EDT 24 Mar 2019 | Cancer Connect

Three CDK inhibitor drugs Ibrance (palbociclib) Kisqali (ribociclib) Verzenio (abemaciclib) are now FDA approved.

Original Article: Cell Cycle-Blocking Drugs Ibrance, Kisqali, Verzenio & Breast Cancer

More From BioPortfolio on "Cell Cycle-Blocking Drugs Ibrance, Kisqali, Verzenio & Breast Cancer"